Budesonide Formoterol Drug Combination + nebulisation of terbutaline

Phase 3Terminated
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Asthma in Children

Conditions

Asthma in Children

Trial Timeline

Aug 23, 2021 โ†’ Jun 23, 2023

About Budesonide Formoterol Drug Combination + nebulisation of terbutaline

Budesonide Formoterol Drug Combination + nebulisation of terbutaline is a phase 3 stage product being developed by AstraZeneca for Asthma in Children. The current trial status is terminated. This product is registered under clinical trial identifier NCT04705727. Target conditions include Asthma in Children.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04705727Phase 3Terminated